Australia’s active vaccine safety system
Following an unexpected spate of adverse events among children who received one brand of influenza vaccine in 2010, a review was conducted by Professor John Horvath into responses to adverse events following immunisation. One of these recommendations included the establishment of an active system of monitoring adverse events following immunisation, which led to the establishment of AusVaxSafety in 2014.
Until then, adverse events were primarily monitored through a passive system administered by the Therapeutic Goods Administration (TGA), which relies on the parent or the patient reporting any adverse reactions to their general practitioner (GP). However, this can be time-consuming and depends on the patient actually notifying their doctor about the adverse event(s), and the GP reporting them on to the TGA. This problem prompted clinicians, academics and different levels of government across Australia to start looking at more robust and timely ways of monitoring adverse events following immunisation.
AusVaxSafety, led by the National Centre for Immunisation Research and Surveillance and funded by the Australian Government Department of Health, was initially established as a collaborative initiative to actively monitor the safety of influenza vaccines in children aged <5 years using automated SMS technology to solicit feedback from vaccine recipients and parents.
In recent years AusVaxSafety has further expanded to conduct active surveillance of seasonal influenza vaccine in people aged 6 months and older (including pregnant women), pertussis booster vaccine safety in children aged 12 months to 6 years, zoster vaccine in adults aged 70–79 years, human papillomavirus (HPV) vaccine in adolescents aged 11–14 years and pertussis booster vaccine in pregnant women.
From 2016 two new projects were also funded under AusVaxSafety: Adverse Events Following Immunisation-Clinical Assessment Network and vaccine safety in primary healthcare data.
AusVaxSafety has now grown into a world-leading collaboration between immunisation providers, private enterprise, research institutions, state and territory governments and the Australian Government Department of Health, which has significantly improved Australia’s ability to monitor, detect and respond to vaccine safety events.
AusVaxSafety receives fundingfrom the Australian Government
NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090
We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.
Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.
Stay updated with the latest from NCIRS
Stay updated with the latest from ausvax